Tuesday, July 24, 2012

Bromocriptine mesylate - A dopamine agonist has efficacy in Type 2 diabetes

Age old drug Bromocriptine mesylate, which is widely prescribed in India for a wide range of disease (parkinson, female infertility, Male hyperprolactinaemia, Benign Breast diseases, Acromegaly, Galactorrhoea) is also efficacious for the treatment of type 2 diabetes. In May 2009, this drug Bromocriptine mesylate was approved by the USFDA for the treatment of type 2 diabetes.  The drug is marketed under the brand name Cycloset for type 2 diabetes in the US.
The approval of Cycloset in Type 2 diabetes by the USFDA was based on a 52-weekclincial trial evaluating 3070 patients. In the year long trial of 3,070 adults with type 2 diabetes, Cycloset demonstrated superiority over  placebo at improving HbA1c levels. In that trial, 39% of patients taking Cycloset met the HbA1c goal, compared to 11% of patients taking the placebo.